Compare Novavax Inc (NVAX) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Sun Life Financial Inc. Common Stock — how do they compare? Novavax Inc trades at $12.4 (market cap $2.08B), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.44B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 20.9× Novavax Inc's market cap, and Sun Life Financial Inc. Common Stock pays a 3.47% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| NVAX | SLF | |
|---|---|---|
Market Cap | $2.08B | $43.44B |
Volume | 8,501,139 | 333,821 |
Sector | Health | Financials |
52-Week High | $12.82 | $84.07 |
52-Week Low | $6.22 | $57.60 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.66B | $45.17B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
